Bryn Mawr Capital Management LLC Buys 1,788 Shares of Becton, Dickinson and Company (NYSE:BDX)

Bryn Mawr Capital Management LLC boosted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 25.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 8,939 shares of the medical instruments supplier’s stock after purchasing an additional 1,788 shares during the period. Bryn Mawr Capital Management LLC’s holdings in Becton, Dickinson and Company were worth $2,028,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of BDX. State Street Corp lifted its position in shares of Becton, Dickinson and Company by 0.8% during the 3rd quarter. State Street Corp now owns 13,953,116 shares of the medical instruments supplier’s stock valued at $3,364,096,000 after buying an additional 106,616 shares in the last quarter. Geode Capital Management LLC raised its stake in Becton, Dickinson and Company by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 6,285,513 shares of the medical instruments supplier’s stock worth $1,510,050,000 after acquiring an additional 111,101 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in Becton, Dickinson and Company by 9.4% during the third quarter. Massachusetts Financial Services Co. MA now owns 5,365,554 shares of the medical instruments supplier’s stock valued at $1,293,635,000 after purchasing an additional 460,440 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Becton, Dickinson and Company by 79.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock worth $720,089,000 after purchasing an additional 1,317,723 shares during the period. Finally, Nordea Investment Management AB increased its stake in shares of Becton, Dickinson and Company by 31.0% in the fourth quarter. Nordea Investment Management AB now owns 2,844,566 shares of the medical instruments supplier’s stock worth $647,082,000 after purchasing an additional 673,568 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on BDX shares. Piper Sandler lifted their target price on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, January 28th. Barclays upped their price objective on Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. Finally, StockNews.com downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Tuesday. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, Becton, Dickinson and Company presently has a consensus rating of “Moderate Buy” and an average price target of $278.29.

Insiders Place Their Bets

In related news, Director Jeffrey William Henderson bought 1,500 shares of the company’s stock in a transaction dated Monday, February 10th. The stock was purchased at an average price of $233.62 per share, for a total transaction of $350,430.00. Following the acquisition, the director now owns 8,015 shares in the company, valued at $1,872,464.30. This trade represents a 23.02 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Bertram L. Scott sold 700 shares of the business’s stock in a transaction that occurred on Wednesday, February 12th. The shares were sold at an average price of $227.99, for a total value of $159,593.00. Following the transaction, the director now directly owns 36,033 shares in the company, valued at approximately $8,215,163.67. This represents a 1.91 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,544 shares of company stock valued at $2,370,309 in the last three months. Corporate insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Price Performance

NYSE:BDX opened at $227.46 on Thursday. The business’s 50-day moving average is $233.11 and its 200 day moving average is $233.17. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $251.99. The company has a market capitalization of $65.31 billion, a P/E ratio of 37.78, a P/E/G ratio of 1.63 and a beta of 0.40. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. On average, equities research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be given a dividend of $1.04 per share. The ex-dividend date is Monday, March 10th. This represents a $4.16 annualized dividend and a yield of 1.83%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 69.10%.

Becton, Dickinson and Company declared that its board has approved a share repurchase program on Tuesday, January 28th that permits the company to buyback 10,000,000 shares. This buyback authorization permits the medical instruments supplier to purchase shares of its stock through open market purchases. Shares buyback programs are often an indication that the company’s management believes its shares are undervalued.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.